Acute liver failure is a life-threatening condition in the absence of liver transplantation option. The aetiology of liver failure is the most important factor determining the probability of native liver recovery and prognosis of the patient. Extracorporeal liver assist devices like MARS (Molecular Adsorbent Recirculating System) may buy time for native liver recovery or serve as bridging therapy to liver transplantation, with reduced risk of cerebral complications. MARS treatment may alleviate hepatic encephalopathy even in patients with a completely necrotic liver. Taking this into account, better prognostic markers than hepatic encephalopathy should be used to assess the need for liver transplantation in acute liver failure.
MitznerSRStangeJKlammtS: Albumin dialysis MARS: Knowledge from 10 years of clinical investigation. ASAIO J2009;55:498–502.
2.
European Liver Transplant Registry 2009 — The European Liver and Intestinal Transplant Association (ELITA). http://www.ELTR.org.
3.
LeeWMSquiresRHJrNybergSL: Acute liver failure: Summary of a workshop. Hepatology2008;47:1401–1415.
4.
TreyCDavidsonCS: The management of fulminant hepatic failure. Prog Liver Dis1970;3:282–298.
5.
O'GradyJGSchalmSWWilliamsR: Acute liver failure: Redefining the syndromes. Lancet1993;342(8866):273–275.
6.
RiordanSMWilliamsR: Perspectives on liver failure: Past and future. Semin Liver Dis2008;28:137–141.
7.
LeeWM: Etiologies of acute liver failure. Semin Liver Dis2008;28:142–153.
8.
OstapowiczGFontanaRJSchiodtFV: Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Inter Med2002;137:947–954.
9.
BrandsaeterBHockerstedtKFrimanS: Fulminant hepatic failure: Outcome after listing for highly urgent liver transplantation-12 years experience in the Nordic countries. Liver Transpl2002;8:1055–1062.
10.
SalibaFCamusCDurandF: Randomized controlled multicenter trial evaluating the efficacy and safety of albumin dialysis with MARS in patients with fulminant and subfulminant hepatic failure. Hepatology2008;48:4 (Suppl 1): LB1.
11.
BernalWCrossTJAuzingerG: Outcome after waitlisting for emergency liver transplantation in acute liver failure: A single centre experience. J Hepatol2009;50:306–313.
12.
BjøroKKirkegaardPEriczonBG: Is a 3-day limit for highly urgent liver transplantation for fulminant hepatic failure appropriate, and is the diagnosis in some cases incorrect? Transplant Proc2001;33:2511–2513.
13.
O'GradyJGAlexanderGJHayllarKM: Early indicators of prognosis in fulminant hepatic failure. Gastroenterology1989;97:439–445.
14.
BaileyBAmreDKGaudreaultP: Fulminant hepatic failure secondary to acetaminophen poisoning: A systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med2003;31:299–305.
15.
McPhailMJWendonJABernalW: Meta-analysis of performance of Kings's College Hospital Criteria in prediction of outcome in non-paracetamol-induced acute liver failure. J Hepatol2010;53(3):492–499.
16.
PolsonJ: Assessment of prognosis in acute liver failure. Semin Liver Dis2008;28:218–226.
17.
BernuauJGoudeauAPoynardT. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology1986;6:648–651.
18.
BernalWDonaldsonNWyncollDWendonJ: Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: A cohort study. Lancet2002;359(9306):558–563.
19.
SchmidtLEDalhoffK: Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology2005;41:26–31.
20.
SteadmanRHVan RensburgAKramerDJ: Transplantation for acute liver failure: Perioperative management. Curr Opin Organ Transplant2010;15:368–373.
21.
DevlinJWendonJHeatonN: Pretransplantation clinical status and outcome of emergency transplantation for acute liver failure. Hepatology1995;21:1018–1024.
22.
SchiodtFVChungRTSchilskyML: Outcome of acute liver failure in the elderly. Liver Transpl2009;15:1481–1487.
UmeshitaKFujiwaraKKiyosawaK: Operative morbidity of living liver donors in Japan. Lancet2003;362(9385):687–690.
25.
QuagliaAPortmannBCKniselyAS: Auxiliary transplantation for acute liver failure: Histopathological study of native liver regeneration. Liver Transpl2008;14:1437–1448.
26.
FarmerDGAnselmoDMGhobrialRM: Liver transplantation for fulminant hepatic failure: Experience with more than 200 patients over a 17-year period. Ann Surg2003;237:666–675.
27.
LeitheadJAFergusonJWBatesCM: The systemic inflammatory response syndrome is predictive of renal dysfunction in patients with non-paracetamol-induced acute liver failure. Gut2009;58:443–449.
28.
EdeRJGimsonAEBihariD: Controlled hyperventilation in the prevention of cerebral oedema in fulminant hepatic failure. J Hepatol1986;2:43–51.
29.
FordRMSakariaSSSubramanianRM: Critical care management of patients before liver transplantation. Transplant Rev (Orlando)2010;24:190–206.
30.
StravitzRTLarsenFS: Therapeutic hypothermia for acute liver failure. Crit Care Med2009;37 (7 Suppl):S258–S264.
31.
McKenzieTJLillegardJBNybergSL: Artificial and bioartificial liver support. Semin Liver Dis2008;28:210–217.
32.
DemetriouAABrownRSJrBusuttilRW: Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg2004;239:660–670.
33.
Van de KerkhoveMPHoekstraRChamuleauRA: Clinical application of bioartificial liver support systems. Ann Surg2004;240:216–230.
34.
O'GradyJGGimsonAEO'BrienCJ: Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology1988;94:1186–1192.
35.
LarsenFSWendonJHockerstedtK: Liver assisting with high-volume plasma exchange in patients with acute liver failure. Hepatology2010;52 (Suppl 1):376A114.
36.
FalkenhagenDStroblWVogtG: Fractionated plasma separation and adsorption system: A novel system for blood purification to remove albumin bound substances. Artif Organs1999;23:81–86.
37.
SenturkEEsenFOzcanPE: The treatment of acute liver failure with fractionated plasma separation and adsorption system: Experience in 85 applications. J Clin Apher2010;25:195–201.
38.
GrodzickiMKotulskiMLeonowiczD: Results of treatment of acute liver failure patients with use of the prometheus FPSA system. Transplant Proc2009;41:3079–3081.
39.
MeijersBKVerhammePNevensF: Major coagulation disturbances during fractionated plasma separation and adsorption. Am J Transplant2007;7:2195–2199.
40.
LaiWKHaydonGMutimerD: The effect of molecular adsorbent recirculating system on pathophysiological parameters in patients with acute liver failure. Intensive Care Med2005;31:1544–1549.
41.
LeeKHLeeMKSutedjaDS: Outcome from molecular adsorbent recycling system (MARS) liver dialysis following drug-induced liver failure. Liver Int2005;25:973–977.
42.
ZhouXMMiaoJYYangY: Clinical experience with molecular adsorbent recirculating system (MARS) in patients with drug-induced liver failure. Artif Organs2004;28:483–486.
43.
KantolaTKoivusaloAHöckerstedtK: The effect of molecular adsorbent recirculating system on survival, native liver recovery, and need for liver transplantation in acute liver failure patients. Transpl Int2008;21:857–866.
44.
CamusCLavoueSGacouinA: Liver transplantation avoided in patients with fulminant hepatic failure who received albumin dialysis with the molecular adsorbent recirculating system while on the waiting list: Impact of the duration of therapy. Ther Apher Dial2009;13:549–555.
45.
NovelliGRossiMPretagostiniM: One hundred sixteen cases of acute liver failure treated with MARS. Transplant Proc2005;37:2557–2559.
46.
SteinerCMitznerS: Experiences with MARS liver support therapy in liver failure: Analysis of 176 patients of the International MARS Registry. Liver2002;22 (Suppl 2):20–25.
47.
CamusCLavoueSGacouinA: Molecular adsorbent recirculating system dialysis in patients with acute liver failure who are assessed for liver transplantation. Intensive Care Med2006;32:1817–1825.
48.
ParésADeulofeuRCisnerosL: Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. Crit Care2009;13:R8.
49.
GuoLMLiuJYXuDZ: Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome. Liver Int2003;23 (Suppl 3):16–20.
50.
KoivusaloAMKantolaTArolaJ: Is it possible to gain extra waiting time to liver transplantation in acute liver failure patients using albumin dialysis? Ther Apher Dial2009;13:413–418.
51.
KoivusaloAMTeikariTHöckerstedtK: Albumin dialysis has a favorable effect on amino acid profile in hepatic encephalopathy. Metab Brain Dis2008;23:387–398.
52.
KantolaTKoivusaloAMParmanenS: Survival predictors in patients treated with a molecular adsorbent recirculating system. World J Gastroenterol2009;15:3015–3024.
53.
KantolaTMäklinSKoivusaloAM: Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure. World J Gastroenterol2010;16:2227–2234.
54.
WiggAJGunsonBKMutimerDJ: Outcomes following liver transplantation for seronegative acute liver failure: Experience during a 12-year period with more than 100 patients. Liver Transpl2005;11:27–34.
